Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sufentanil + lidocaine is a combination pharmacological protocol used for feticide during late-term termination of pregnancy (after 22 weeks' gestation). This protocol, utilized as a standard-of-care control in clinical research by the University Hospital, Montpellier, involves the sequential or combined administration of sufentanil and lidocaine. Sufentanil, a potent synthetic opioid, acts as a mu-opioid receptor agonist to provide fetal analgesia and sedation. Lidocaine, a local anesthetic, acts as a sodium channel blocker that inhibits the depolarization of cardiac myocytes (primarily via SCN5A), leading to rapid fetal cardiac asystole. The combination is typically administered via ultrasound-guided umbilical vein puncture or direct intracardiac injection to ensure fetal death prior to the induction of labor, addressing legal and ethical requirements for late-term terminations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sufentanil + lidocaine.